PTSD Clinical Trial - Enhancing the Effectiveness of Prolonged Exposure

Status Recruiting

Clinical Trial Summary

The long-term goal of this study is to reduce suicidal thoughts and behaviors among treatment-seeking individuals who also have posttraumatic stress disorder (PTSD). Prolonged exposure (PE) and crisis response plan (CRP) have demonstrated empirical support for reducing suicide attempts as compared to treatment as usual. However, no studies to date have assessed their effectiveness when used in combination. In light of this knowledge gap, the primary objective of this study will be to test the effectiveness of PE augmented with CRP as compared to PE with care as usual (self-guided treatment plan), an active comparator, for the reduction of suicide ideations and attempts for individuals with comorbid PTSD.

Clinical Trial Description

Posttraumatic stress disorder (PTSD) is associated with a host of functional problems and negative outcomes, including occupational and marital dissatisfaction, violence, alcohol and substance abuse, and suicide. Cognitive behavioral treatments tend to be the most highly efficacious treatments for PTSD. Prolonged Exposure (PE) therapy is a manualized cognitive behavioral therapy consisting of imaginal exposure followed by processing thoughts and feelings related to the imaginal experience; in-vivo exposure, psychoeducation, and controlled breathing training. Preliminary evidence suggests that PE is associated with significant suicidal ideation (SI) reductions. Enhancing PE with procedures that have been shown to significantly reduce suicidal thoughts and behaviors could serve to further reduce suicide risk during and after treatment completion. The long-term goal of this project is to prevent suicides among individuals diagnosed with PTSD by integrating trauma-focused therapies with suicide-focused interventions. The primary objective of this pilot project is to test the efficacy of PE when enhanced with a crisis response plan utilizing self-report, behavioral, and ecological assessment methods to compare treatment effects. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06285708
Study type	Interventional
Source	Ohio State University
Contact	Jaryd Hiser, Ph.D.
Phone	614-814-0163
Email	jaryd.hiser@osumc.edu
Status	Recruiting
Phase	N/A
Start date	February 2024
Completion date	January 2026

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03962504` - Written Exposure Therapy Versus Prolonged Exposure: a Non-inferiority Trial	N/A
Completed	`NCT01995123` - Behavioral Activation for Smoking Cessation in PTSD	N/A
Not yet recruiting	`NCT06278922` - Evaluating Signs of Safety: A Deaf-Accessible Therapy Toolkit for AUD and Trauma	N/A
Completed	`NCT04597450` - Lu AG06466 in Participants With Post Traumatic Stress Disorder (PTSD)	Phase 1
Completed	`NCT03593772` - Mission Reconnect- Delivering a Mobile and Web Based Self Directed Complementary And Integrative Health Program to Veterans and Their Partners to Manage Pain and PTSD	N/A
Completed	`NCT03429166` - Connecting Women to Care: Home-based Psychotherapy for Women With MST Living in Rural Areas	N/A
Recruiting	`NCT04317820` - Deep Brain Reorienting in Post-traumatic Stress Disorder	N/A
Active, not recruiting	`NCT04588883` - Strengthening Families Living With HIV in Kenya	N/A
Completed	`NCT03504722` - Evaluating the Feasibility of RESCUE: An Adjunctive HAI-Based Intervention for Veterans With PTSD	N/A
Completed	`NCT04305353` - Intensive Care Unit (ICU) Diary Project	N/A
Completed	`NCT03113890` - McLean and Genomind Prospective Study	N/A
Not yet recruiting	`NCT05921929` - First-In-Human (FIH), Single Ascending Dose (SAD) Study of FluoroEthylNorMemantine (FENM)	Phase 1
Withdrawn	`NCT05173831` - Study of Feasibility and Safety of MDMA-Assisted Group Therapy for the Treatment of PTSD in Veterans	Phase 2
Withdrawn	`NCT03924297` - Chilipad for Sleep and Symptoms of PTSD	N/A
Not yet recruiting	`NCT04056767` - Changes in Digital Phenotype During PE Therapy
Completed	`NCT03343028` - Biomarker Establishment for Superior Treatment of PTSD
Withdrawn	`NCT03216356` - Effect of D-cycloserine on a Short Imagery Rescripting Intervention for Subclinical PTSD	Phase 2/Phase 3
Completed	`NCT03158558` - Intensive Weekend Retreat Multi-Couple Group Therapy for PTSD	N/A
Completed	`NCT02370173` - A Non-Pharmacological Method for Enhancing Sleep in PTSD	N/A
Withdrawn	`NCT01957371` - Mindful Yoga Therapy for Veterans With PTSD and Pain	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Enhancing the Effectiveness of Prolonged Exposure Among Suicidal Individuals With PTSD

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms